BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
MWN-AI** Summary
BioRestorative Therapies, Inc. (NASDAQ: BRTX), a company focused on regenerative medicine utilizing stem cell-based therapies, has announced that it will release its financial results for the third quarter of 2025 on November 12, 2025, following the market's close. The company will also host a conference call at 4:30 PM ET to discuss these results and provide a comprehensive business update.
BioRestorative is recognized for its innovative approaches to treating disc and spine disorders and metabolic diseases through its two main clinical programs. The first is the brtxDISC™ program, which features BRTX-100, a cell therapy derived from a patient's own cultured mesenchymal stem cells. This therapy aims to treat chronic lower back pain from degenerative disc disease, for which it has commenced a Phase 2 clinical trial. Additionally, BRTX-100 has received FDA Investigational New Drug clearance for testing against chronic cervical discogenic pain.
The second program, named ThermoStem®, focuses on developing therapies targeting obesity and metabolic disorders by utilizing brown adipose derived stem cells. Initial studies indicate that increasing brown fat levels may enhance caloric expenditure and lower glucose levels, offering significant potential in combating obesity and diabetes.
Furthermore, BioRestorative operates a commercial BioCosmeceutical platform, featuring a proprietary biologic serum that aims to improve cosmetic concerns like fine lines and wrinkles through cell-based secretomes. As it looks to the future, the company plans to expand its commercial offerings within this sector.
For those interested, the conference call will be accessible via phone and streamed live on the company’s website, with archived access also provided. This upcoming financial release and subsequent call are critical for stakeholders looking to understand BioRestorative's developments in the dynamic field of regenerative medicine.
MWN-AI** Analysis
As BioRestorative Therapies prepares to release its third-quarter financial results on November 12, 2025, investors should carefully assess several factors that could impact the company's stock performance. The upcoming conference call presents a strategic opportunity for management to clarify operational progress, particularly in their clinical programs related to spinal and metabolic therapies.
BioRestorative's lead product, BRTX-100, targets painful lumbosacral disc disorders and is currently in Phase 2 trials. Positive updates regarding efficacy and patient outcomes could significantly bolster investor sentiment and drive stock prices upward. Conversely, any negative data or delays in trials may raise concerns about the product’s market viability and affect the stock adversely.
Another area worth noting is the company’s endeavors in metabolic disorders through its ThermoStem program. As obesity and diabetes-related issues continue to rise, the success of BADSC in preclinical studies has positioned BioRestorative in a lucrative market. Strong results could open avenues for potential partnerships or collaborations with larger pharmaceutical companies, enhancing their growth profile.
Additionally, the BioCosmeceuticals division addresses an emerging market in regenerative aesthetic treatments. Expanding this product line could pave the way for diverse revenue streams. Investors should pay particular attention to any developments regarding regulatory approvals, especially in light of the competitive nature of the industry.
As for market sentiment, it’s essential for investors to monitor broader market conditions and investor appetite for biotech stocks, which can be volatile and sensitive to clinical news. Preparing for potential fluctuations post-announcement is prudent.
In conclusion, while BioRestorative’s innovative focus and product pipeline suggest growth potential, investors should remain vigilant regarding clinical updates and market dynamics as they approach the third-quarter results.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.
Third Quarter 2025 Results Conference Call Details:
| Date: | Wednesday, November 12, 2025 | |
| Time: | 4:30 p.m. ET | |
| Domestic: | 1-888-506-0062 | |
| International: | 1-973-528-0011 | |
| Access Code: | 464585 |
The call will also be broadcast live and archived on the Company's website under News & Events/IR Calendar in the Investors section.
About BioRestorative Therapies, Inc.
BioRestorative ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem ® ): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ**
What specific financial metrics or developments should investors anticipate from BioRestorative Therapies Inc BRTX in the upcoming third-quarter 2025 earnings report, particularly regarding revenue from its Disc/Spine and Metabolic programs?
How is BioRestorative Therapies Inc BRTX positioned to compete in the regenerative medicine market, especially with its focus on stem cell-based therapies and emerging BioCosmeceutical products?
Can BioRestorative Therapies Inc BRTX provide any updates on the progress and expected timelines for the Phase 2 clinical trials of BRTX-100 for chronic lower back pain and its IND application for chronic cervical discogenic pain?
What measures is BioRestorative Therapies Inc BRTX taking to mitigate the risks and uncertainties mentioned in its forward-looking statements, especially regarding FDA approvals for its innovative therapies and product lines?
**MWN-AI FAQ is based on asking OpenAI questions about BioRestorative Therapies Inc (NASDAQ: BRTX).
NASDAQ: BRTX
BRTX Trading
1.47% G/L:
$0.2968 Last:
3,129,686 Volume:
$0.2613 Open:
